Therapeutic targeting of cancer cell metabolism: Role of metabolic enzymes, oncogenes and tumor suppressor genes

Journal of Cancer Science and Therapy

Volumn 4, Issue 9, 2012, Pages 281-291

  Majeed, Rabiya ^a   Hamid, Abid ^a   Qurishi, Yasrib ^a   Qazi, Asif Khurshid ^a   Hussain, Aashiq ^a   Ahmed, Mudassier ^a   Najar, Rauf Ahmad ^a   Bhat, Javeed Ahmad ^a   Singh, Shashank Kumar ^a   Saxena, Ajit Kumar ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Cancer therapy; Glutaminolysis; Glycolysis; Hexokinase; Hypoxia; Oncogenes; Tumorigenesis

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 6 PHOSPHOFRUCTO 2 KINASE; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUTAMINASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 90; HEXOKINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOGLYCERATE KINASE; PICTILISIB; PROTEIN KINASE B; PROTEIN P53; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE KINASE; RAS PROTEIN; TRANSKETOLASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; XL 147; XL 418; XL 765;

CANCER CELL METABOLISM; CANCER GROWTH; CARCINOGENESIS; CELL METABOLISM; CELL PROLIFERATION; ENERGY YIELD; EPIGENETICS; GENE MUTATION; GLYCOLYSIS; HUMAN; METABOLIC REGULATION; NONHUMAN; ONCOGENE; ONCOGENE MYC; ONCOGENE RAS; OUTCOME ASSESSMENT; OXIDATIVE PHOSPHORYLATION; PERSONALIZED MEDICINE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 84867567280     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000156     Document Type: Review

References (91)

1. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
2. Fritz V, Fajas L (2010) Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene 29: 4369-4377.
3. Marín-Hernández A, Rodríguez-Enríquez S, Vital-González PA, Flores Rodríguez FL, Macías-Silva M, et al. (2006) Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over expressed but strongly product-inhibited hexokinase. FEBS J 273: 1975-1988.
4. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer's double edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777-4786.
5. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 19: 17-24.
6. Bartrons R, Caro J (2007) Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr 39: 223-229.
7. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, et al. (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62: 5881-5887.
8. Minchenko O, Opentanova I, Caro J (2003) Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2- 6-bisphosphatase gene family (PFKFB 1-4) expression in vivo. FEBS Lett 554: 264-270.
9. Šmerc A, Sodja E, Legiša M (2011) Posttranslational Modification of 6-phosphofructo-1-kinase as an Important Feature of Cancer Metabolism. Plos One 6: 19645.
10. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E (2005) Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308.
11. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC (2008) Pyruvate kinase M2 is a phosphotyrosine binding protein. Nature 452: 181-186.
12. Marshall S, Bacote V, Traxinger RR (1991) Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266: 4706-4712.
13. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233.
14. David CJ, Chen M, Assanah M, Canoll P, Manley JL (2009) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-368.
15. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, et al. (2002) Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 22: 311-318.
16. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185.
17. Cairns RA, Papandreou I, Sutphin PD, Denko NC (2007) Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci U S A 104: 9445-9450.
18. Levine AJ, Puzio-Kuter AM (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330: 1340-1344.
19. Erickson JW, Cerione RA (2011) Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget 1: 734-740.
20. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-19.
21. Hammoudi N, Ahmed KB, Garcia-Prieto C, Huang P (2011) Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer 30: 508-525.
22. Hegymegi-Barakonyi B, Eros D, Szántai-Kis C, Breza N, Bánhegyi P, et al. (2009) Tyrosine kinase inhibitors small molecular weight compounds inhibiting EGFR. Curr Opin Mol Ther 11: 308-321.
23. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
24. Kuhajda FP (2008) AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int J Obes 32: 36-41.
25. Shackelford DB, Shaw RJ (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nature Rev Cancer 9: 563-575.
26. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707.
27. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835.
28. Medina RA, Owen GI (2002) Glucose transporters: expression, regulation and cancer. Biol Res 35: 9-26.
29. Wood IS, Trayhurn P (2003) Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 89: 3-9.
30. Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ, et al. (2000) Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res 60: 6178-6183.
31. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV (2007) Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase1. Mol Cell Biol 27: 7381-7393.
32. Osthus RC, Shim H, Kim S, Li Q, Reddy R, et al. (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275: 21797-21800.
33. Kim J, Lee JH, Iyer VR (2008) Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One 3: e1798.
34. Morrish F, Neretti N, Sedivy JM, Hockenbery DM (2008) The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 7: 1054-1066.
35. Menendez JA, Colomer R, Lupu R (2005) Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med Hypotheses 64: 342-349.
36. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279: 80-90.
37. Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20: 87-90.
38. Plas DR, Thompson CB (2005) Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 7435-7442.
39. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
40. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, et al. (2004) AAkt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
41. Barthel A, Okino ST, Liao J, Nakatani K, Li J, et al. (1999) RRegulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem 274: 20281-20286.
42. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, et al. (2001) Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15: 1406-1418.
43. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, et al. (1982) Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323-1329.
44. Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, et al. (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24: 6465-6481.
45. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB (2005) ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24: 6314-6322.
46. Fang M, Shen Z, Huang S, Zhao L, Chen S, et al. (2010) The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 143: 711-724.
47. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
48. Robey RB, Hay N (2009) Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19: 25-31.
49. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
50. Semenza GL (2000) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88: 1474-1480.
51. Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ (2005) Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 7: 324-330.
52. Minchenko O, Opentanova I, Caro J (2003) Hypoxic regulation of the 6-phos-phofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett 554: 264-270.
53. Simon MC (2006) Coming up for air: HIF-1 and mitochondrial oxygen consumption. Cell Metab 3: 150-151.
54. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, et al. (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120.
55. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, et al. (2006) p53 regulates mitochondrial respiration. Science 312: 1650-1653.
56. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, et al. (2007) The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 67: 3043-3053.
57. Feng Z, Zhang H, Levine AJ, Jin S (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 102: 8204-8209.
58. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
59. Dali-Youcef N, Mataki C, Coste A, Messaddeq N, Giroud S, et al. (2007) Adipose tissue-specific inactivation of the retinoblastoma protein protects against diabesity because of increased energy expenditure. Proc Natl Acad Sci U S A 104: 10703-10708.
60. Tennant DA, Durán RV, Gottlieb E (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277.
61. Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, et al. (2010) 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol 11: 510-517.
62. Hammoudi N, Ahmed KB, Garcia-Prieto C, Huang P (2011) Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer 30: 508-525.
63. Clem B, Telang S, Clem A, Yalcin A, Meier J, et al. (2008) Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 7: 110-120.
64. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC (2008) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181-186.
65. Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, et al. (2010) Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 79: 1118-1124.
66. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, et al. (1997) c-Myc transactivation of LDHA: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 94: 6658-6663.
67. Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, et al. (2010) Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res 70: 10351-10361.
68. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, et al. (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 107: 2037-2042.
69. Thomas AA, Le Huerou Y, De Meese J, Gunawardana I, Kaplan T, et al. (2008) Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors. Bioorg Med Chem Lett 18: 2206-2210.
70. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, et al. (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18: 207-219.
71. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
72. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102: 932-941.
73. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
74. Knight ZA, Shokat KM (2007) Chemically targeting the PI3K family. Biochem Soc Trans 35: 245-249.
75. Marone R, Cmiljanovic V, Giese B, Wymann MP (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 1784: 159-185.
76. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, et al. (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125: 733-747.
77. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349.
78. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
79. Garlich JR, De P, Dey N, Su JD, Peng X, et al. (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68: 206-215.
80. Hilgard P, Klenner T, Stekar J, Nössner G, Kutscher B, et al. (1997) D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33: 442-446.
81. Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, et al. (2004) In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 14: 513-527.
82. Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, et al. (2006) Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther 5: 713-722.
83. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, et al. (2008) Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68: 2366-2374.
84. Vézina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28: 721-726.
85. Yatscoff RW, LeGatt DF, Kneteman NM (1993) Therapeutic monitoring of rapamycin: a new immunosuppressive drug. Ther Drug Monit 15: 478-482.
86. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nature Rev Drug Discov 5: 671-688.
87. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, et al. (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159.
88. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Activesite inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38.
89. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032.
90. Fujita N, Sato S, Ishida A, Tsuruo T (2002) Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 277: 10346-10353.
91. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N (2003) Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63: 2139-2144.